Cargando…
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
INTRODUCTION: Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases with childhood onset. It comprises different subtypes of which the systemic onset subtype is often resistant to treatment. With the advent of biological treatment with tumor necrosis factor-α (TNFα)-inhibito...
Autor principal: | Herlin, Troels |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899792/ https://www.ncbi.nlm.nih.gov/pubmed/20694074 |
Ejemplares similares
-
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012) -
Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023) -
Identifying acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis in children
por: Brix, Ninna, et al.
Publicado: (2020) -
Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011) -
Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)